The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on 21 February ten new medicines for approval. These include a number of medicines for the treatment of chronic obstructive pulmonary disease (COPD). Four of these, Anoro (umeclidinium bromide / vilanterol) and Laventair (umeclidinium bromide / vilanterol), as well as Incruse (umeclidinium bromide) and Ulunar Breezhaler (indacaterol / glycopyrronium bromide), are intended for the treatment of symptoms in adult patients with COPD. The remaining two, DuoResp Spiromax (budesonide / formoterol) and BiResp Spiromax (budesonide / formoterol), are intended for the treatment of asthma and COPD.
February 24th, 2014 | Published in Uncategorized,